AtaiBeckley Shares Rise on Reports of Potential Acquisition by Eli Lilly

Shares of AtaiBeckley surged as much as 53% in premarket trading following reports that Eli Lilly is considering acquiring the psychedelic drug developer. Analysts suggest such a deal could enhance Lilly's neuroscience portfolio and diversify its therapeutic focus beyond cardiometabolic diseases.

By Fiona Craig Thu, July 16, 2026 at 1:30 PM GMT+3 1 min read · Yahoo Finance · July 16, 2026, 10:30 UTC

AtaiBeckley Shares Rise on Reports of Potential Acquisition by Eli Lilly

Tickers: $ATAI $LLY

Topics: Neuroscience Portfolio Pharmaceuticals Takeover Talks

Read the full article at Yahoo Finance

More World news

Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC
Bit Digital Reports Q3 2026 Net Income of $28.5 Million Amid Revenue Decline Motley Fool · November 12, 2026, 18:26 UTC
EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC
Sabre Corp Shares Decline Following Travelport Denial of Merger Speculation Seeking Alpha · November 12, 2026, 18:21 UTC
Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC
MGP Ingredients Rebrands to Sempreon and Announces Strategic Shift Toward Ready-to-Drink Products Motley Fool · November 12, 2026, 18:15 UTC
ICON Reports Q3 2026 Revenue of $2 Billion and Accelerating Book-to-Bill Ratio Motley Fool · November 12, 2026, 18:15 UTC
Beachbody (BODi) Reduces Annual Revenue Breakeven to $125 Million Amid Strategic Pivot Motley Fool · November 12, 2026, 18:15 UTC
Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC